# A Bioequivalence Study of Two Different Dosage Form of Genakumab

> **NCT06451848** · PHASE1 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 178 (actual)

## Conditions studied

- Gouty Arthritis (GA)

## Interventions

- **DRUG:** Genakumab Injection (T, Solution for injection)
- **DRUG:** Genakumab for Injection (R, Powder for solution for injection)

## Key facts

- **NCT ID:** NCT06451848
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-24
- **Primary completion:** 2024-11-29
- **Final completion:** 2025-01-10
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06451848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06451848, "A Bioequivalence Study of Two Different Dosage Form of Genakumab". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06451848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*